Univariate analysis of prognostic factors for OS, CSS, and PFS survival
| Features . | P by log-rank test . | ||
|---|---|---|---|
| OS . | CSS . | PFS . | |
| Ann Arbor stage IV | .0004 | .0034 | .0009 |
| Poor performance status (ECOG2 or higher) | NS | NS | NS |
| Presence of B symptoms | .007 | NS | NS |
| Elevated LDH level | .0396 | NS | .0027 |
| Extranodal involvement (2 sites or more) | .0051 | .0143 | .0013 |
| Age older than 60 y | NS | NS | NS |
| Elevated β2-microglobulin level | NS | .0357 | NS |
| Presence of nodal involvement | .0034 | .0004 | .0123 |
| Percentage of large cell infiltration (> 10%) | NS | NS | NS |
| IPI intermediate-high/high risk group | .0071 | .0035 | .0013 |
| Anthracycline-based chemotherapy | NS | NS | NS |
| Autoimmune disease | NS | NS | NS |
| HCV infection | NS | NS | NS |
| Bone marrow involvement | NS | NS | NS |
| Pattern of dissemination (multiple MALT sites only versus other stage IV) | .0001 | .0024 | .0038 |
| Features . | P by log-rank test . | ||
|---|---|---|---|
| OS . | CSS . | PFS . | |
| Ann Arbor stage IV | .0004 | .0034 | .0009 |
| Poor performance status (ECOG2 or higher) | NS | NS | NS |
| Presence of B symptoms | .007 | NS | NS |
| Elevated LDH level | .0396 | NS | .0027 |
| Extranodal involvement (2 sites or more) | .0051 | .0143 | .0013 |
| Age older than 60 y | NS | NS | NS |
| Elevated β2-microglobulin level | NS | .0357 | NS |
| Presence of nodal involvement | .0034 | .0004 | .0123 |
| Percentage of large cell infiltration (> 10%) | NS | NS | NS |
| IPI intermediate-high/high risk group | .0071 | .0035 | .0013 |
| Anthracycline-based chemotherapy | NS | NS | NS |
| Autoimmune disease | NS | NS | NS |
| HCV infection | NS | NS | NS |
| Bone marrow involvement | NS | NS | NS |
| Pattern of dissemination (multiple MALT sites only versus other stage IV) | .0001 | .0024 | .0038 |
NS indicates not significant.